TAP INTO A NEW POSSIBILITY for depression

COMPANY PRESENTATION

NASDAQ: STIM

November 2023
This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (the "Company") relating to market size and growth and other data about the industry in which the Company operates. These estimates and data involve a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates and data.

Certain statements in this presentation and the accompanying oral commentary are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including statements relating to the Company’s business strategy and financial metrics as well as revenue, operating expense and earnings guidance and projections for future periods, relate to future events or the future financial performance of the Company and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “potential” or other comparable terminology, as well as the negative of such statements. All statements other than statements of historical fact may be deemed to be forward-looking statements, including those concerning any expectations regarding investment returns; any projections of financial information; any statements about historical results that may suggest trends for our business; any statements of the plans, strategies, and objectives of management for future operations; any statements of expectation or belief regarding future events, potential markets or market size, additional indications or technology developments; developments in clinical trials or regulatory review of NeuroStar® Advanced Therapy System for additional indications; and any statements of assumptions underlying any of the items mentioned. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company’s control. These and other important factors may cause actual results, performance or achievements to differ materially from those expressed or implied by such forward-looking statements. The forward-looking statements in this presentation are made only as of the date hereof. Except as required by law, the Company assumes no obligation and does not intend to update these forward-looking statements or to conform these statements to actual results or to changes in the Company’s expectations, assumptions, estimates and projections.
Presenters

Keith Sullivan
President & Chief Executive Officer

Steve Furlong
Executive Vice President, Chief Financial Officer & Treasurer

37+ years of experience

36+ years of experience
Our Mission: Renewing Lives by Transforming Neurohealth

**Prevalence**
Adults with Major Depressive Disorder (MDD) (21 million US adults) or Obsessive-Compulsive Disorder (OCD) (4 million US adults)

**Market Leader**
Market leader in TMS for depression with over 5.9 million treatment sessions and over 162,000 patients treated

**Sales & Customer Support**
Largest direct sales and customer support team in the industry

**Reimbursement**
Broad US reimbursement among commercial and government payors

**Clinical Dataset**
Largest clinical dataset in TMS for depression

**Outcomes Registry**
Largest depression outcomes registry in the world

**Indications & Growth**
New indication opportunities and geographic expansion for growth (Anxious Depression and OCD added 2022)
Patients with Major Depressive Disorder are Underserved

2. Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration

Current Solution: Antidepressant Medications

21.0 MILLION
US Adults suffering from MDD¹

13.9 MILLION
US Patients with MDD being treated¹

6.4 MILLION
Poorly served¹,²,³

• Lack of Efficacy
• Intolerable Side Effects
• Increased Need for Solutions Post-COVID

². Per STAR*D patients that have failed one or more antidepressant trial of adequate dose and duration
³. Journal of Clinical Psychiatry, accessed 3/7/2022
Our Unique Differentiators: Only NeuroStar Has…

**Practice Development Manager**
Delivers the NeuroStar STARS SOLUTION — a proven framework to grow your NeuroStar practice.

**83% Response / 62% Remission**
Clinical results validated with 15 years of data via the largest Outcomes Registry.

**Marketing Spend**
To drive Consumer Awareness and grow the category. Increased brand awareness by 33% in 2022.

---

Limitations of Antidepressant Medications

The largest prospective clinical trial of MDD ever conducted, STAR*D, showed that treatment resistance causes a patient’s chance for remission to decrease with each subsequent medication attempt.

STAR*D Study n = 4,041

NeuroStar Delivers Proven Results

Real World Clinical Rating for Patients with MDD¹

- RESPONSE: Significant relief in depression symptoms - 83%
- REMISSION: Depression went away - 62%

Only NeuroStar Has…
Clinically Proven Durability Established Through 12 Months

Long-term post-acute treatment

<table>
<thead>
<tr>
<th></th>
<th>% of Patients (N=257)</th>
</tr>
</thead>
<tbody>
<tr>
<td>End of Acute</td>
<td>62.3%</td>
</tr>
<tr>
<td>3 Months</td>
<td>41.2%</td>
</tr>
<tr>
<td>6 Months</td>
<td>43.2%</td>
</tr>
<tr>
<td>9 Months</td>
<td>44.4%</td>
</tr>
<tr>
<td>12 Months</td>
<td>47.5%</td>
</tr>
</tbody>
</table>

Response (CGI-S) ≤ 3
Remission (CGI-S) ≤ 2

Only NeuroStar has...
Substantial Body of Clinical Evidence

15 Studies  >1,000 Patients  Resulting in 31 Publications

Safety Record
• 5.9 million+ treatment sessions delivered globally
• Over 162,000 patients treated
• Low discontinuation rate from adverse events ~5%¹

Investigator-initiated Trials
• More than 65 studies with over 1,900 patients
• Wide range of conditions, including anxiety, bipolar disorder, pain, PTSD, addiction, schizophrenia, tinnitus, and others

¹ O’Reardon et al. (2008)
Only NeuroStar has...
Patented Contact Sensing Technology

- The smallest movements can result in a dramatic loss of the prescribed TMS dose
- Even 1 mm movement away from the head can result in 40% loss of the TMS prescribed dose
- Continuous contact sensing solves this problem

Contact Sensing

- Constantly monitors patient contact with the NeuroStar coil and alerts the clinician if the coil loses contact with the scalp or is angled incorrectly
- Only NeuroStar Advanced Therapy provides real-time feedback about the coil’s angle and contact

1mm is the equivalent of 3 grains of salt

Delivers Consistent and Repeatable Treatment
Only NeuroStar has...
Proprietary TrakStar® Data Management System

>162,000
Total NeuroStar patients treated worldwide

>16,542
Total Outcomes Registry patients

World’s Largest Depression Outcomes Registry

TrakStar makes automated large-scale data collection feasible

Contributes to new and future indications

5. Outcomes Registry Peer-reviewed Publications1,2,3,4,5


162,000 Total NeuroStar patients treated worldwide

16,542 Total Outcomes Registry patients

World’s Largest Depression Outcomes Registry

TrakStar makes automated large-scale data collection feasible

Contributes to new and future indications

Only NeuroStar is…
Invested in Understanding the Market

67% of patients with MDD are unhappy with their current treatment

Based on market research study of 500 diagnosed depression patients

Two Distinct Groups

Challenged Optimists

WILLING TO ASK THEIR PHYSICIAN ABOUT NEUROSTAR

Struggling Independents

NO LONGER TRUST THEIR PHYSICIAN
– will seek out other doctor for new treatment

Patients Are Looking for New Treatment Solutions
NeuroStar STARS SOLUTION
Proven Program to Ensure Successful Device Operationalization

**Start**
- REIMBURSEMENT CONSULTING
- TRAKSTAR 1.0
- PHQ-10
- NEUROSTAR TREATMENT ROOM SET UP

**Train**
- FRONT DESK TRAINING
- CONSULTATION TRAINING
- CLINICAL TRAINING
- TRAKSTAR 2.0

**Awareness**
- PRACTICE BRANDING
- WEBSITE BRANDING

**Reach Your Patients**
- PATIENT EMAIL OUTREACH
- PATIENT EDUCATION EVENTS

**Source New Patients**
- DIGITAL MARKETING
- HCP EDUCATIONAL EVENTS
Programs Designed to Help NeuroStar Practices Build Awareness

**CO-OP MARKETING WITH VARIOUS LEVELS OF REIMBURSEMENT**
Designed to increase patient awareness and access to NeuroStar treatment at your practice by expanding marketing efforts in your local area.

**CUSTOMER PORTAL WITH MANY MARKETING ASSETS**
Branded materials as well as co-branded digital and print-ready customizable advertising assets are available to customers at myneurostar.com.
The Largest Direct Sales and Customer Support Team
NeuroStar University

By September 2023, attendees to NSU increased patient treatment 61% more than accounts that did not attend.

A 2-DAY COURSE HELD AT OUR STATE-OF-THE-ART TRAINING CENTER
Practices learn how to achieve the best clinical outcomes and market their NeuroStar business, through a combination of instruction and peer to peer learning.

NSU Utilization Performance Index
Baseline index values are based on January 2022 utilization. Excludes new sites from Classes 2022 and 2023.

Practices that attend NSU consistently outperform practices that do not on a month-to-month basis.

In the month of September 2023, NSU practices performed 61% better than sites that have not attended NSU vs. January 2022.
Offered by the Largest National Providers

<table>
<thead>
<tr>
<th>greenbrook gb</th>
<th>SuccessTMS®</th>
<th>Southern California TMS CENTER</th>
</tr>
</thead>
<tbody>
<tr>
<td>TMS NeuroHealth Centers</td>
<td>Advanced Depression Therapy</td>
<td></td>
</tr>
<tr>
<td>ZC TMS</td>
<td>Elite DNA Therapy Services</td>
<td>Transformations</td>
</tr>
<tr>
<td>Formerly known as Active Recovery TMS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Active path MENTAL HEALTH</td>
<td>LifeStance HEALTH</td>
<td>REFRESH Mental Health</td>
</tr>
<tr>
<td>ALLEVIANT HEALTH CENTERS™ Heal Pain, Restore Hope, Regain Purpose.</td>
<td></td>
<td>Discovery Behavioral Healthcare</td>
</tr>
</tbody>
</table>
Widely Reimbursed

95% Coverage
Estimated to cover 95% of total private payor covered lives in the US for MDD and Anxious Depression

Top 25 US Private Insurers
65+ major US private insurers provide coverage policies representing 300 million covered lives

100% Medicare Coverage
61 million covered lives

New indications paid for by existing codes*

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>90867</th>
<th>90868</th>
<th>90869</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MT Treatment Session</td>
<td>Treatment Session</td>
<td>Subsequent MT Treatment Session</td>
</tr>
</tbody>
</table>

*Anxious depression - same coverage policies as MDD / OCD emerging coverage policies
OCD rTMS Coverage Growing

Neuronetics Tools Driving Awareness

1 National plan
4 BCBS plans

Palmetto Medicare MAC

OCD claims paid via existing codes at the same rates

<table>
<thead>
<tr>
<th>CPT Code</th>
<th>90867</th>
<th>90868</th>
<th>90869</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>MT and Treatment Session</td>
<td>Treatment Session</td>
<td>Subsequent MT and Treatment Session</td>
</tr>
</tbody>
</table>
NeuroStar Advanced Therapy for Mental Health Has Potential to Enhance Physician Practice Economics

- Proven return on investment for physicians
- Meaningful incremental income potential for physician practice
- Recoup capital investment by treating ~12 patients
- Generate ~$8,500 average revenue per patient per course of treatment

**Conclusion:** 1 patient per month can equal $100,000 in practice revenue
### Competitive Positioning

<table>
<thead>
<tr>
<th>Feature</th>
<th>NeuroStar</th>
<th>BrainsWay</th>
<th>magstim</th>
<th>MagVenture</th>
<th>CLOUDTMS</th>
<th>Nexstim</th>
<th>mag &amp; more</th>
</tr>
</thead>
<tbody>
<tr>
<td>Practice Consultants</td>
<td>✓</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Marketing including DTC Advertising</td>
<td>✓</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>FDA-cleared for Anxious Depression</td>
<td>✓</td>
<td>—</td>
<td>✓</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>FDA-cleared for OCD</td>
<td>✓</td>
<td>—</td>
<td>✓</td>
<td>✓</td>
<td>—</td>
<td>✓</td>
<td>—</td>
</tr>
<tr>
<td>FDA-cleared for iTBSTheta Burst</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Contact Sensing</td>
<td>✓</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>World’s Largest MDD Outcomes Registry</td>
<td>✓</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Publications from Depression Registration Trials</td>
<td>12</td>
<td>1</td>
<td>—</td>
<td>1</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

*Additional hardware purchase required*
New indications make NeuroStar the most versatile treatment device in the industry

• STAR*D showed 53% of patients with Major Depression had significant anxiety and were considered to have Anxious Depression\(^1\)

• Anxious depression immediately commercially available

• Real-world data from TrakStar contributed to FDA clearance for anxious depression

An estimated 1.2% of U.S. adults had OCD in the past year

- 4 Million adults with OCD (US)\(^1\)
- 2 Million adults with serious OCD\(^1\)
- 523K adults diagnosed w/OCD\(^2\)
- 235K

2. Definitive Health Diagnosis/Prescription Data: 03/25/22

Japan Roadmap

- Primary international focus is on Japan
- Third largest healthcare spend globally
- Single payor healthcare system
- Shonin approval
- Exclusive distribution agreement with Teijin Pharma
- Reimbursement

Estimated TAM in Japan for Treatment Sessions

- Adults Suffering from MDD 2.4 million
- Treated by a Psychiatrist 655,000
- Failed to achieve remission 475,000
- ~$600 Million Addressable Market
NeuroStar Has the Largest Issued Patent Portfolio of All TMS Companies…

Patent Portfolio
• **37 US / 59 OUS**
  Issued or allowed patents
• **6 US / 7 OUS**
  Pending patent applications

Contact Sensing
Multiple U.S. patents

MT Assist
U.S. patent

Iron Core Magnet
Multiple U.S. patents

...protecting our technical advantage and ensuring freedom to operate globally
The NeuroStar Difference

PROOF

Over 13 years as market leader

ONLY NEUROSTAR HAS...

- The world’s largest depression Patient Outcomes Registry
- Proven long-term durability
- Contact Sensing
- TrakStar® – manage/track/report
- TouchStar™– theta burst
- 30 Publications including 12 in depression registry trials

PEOPLE

Team dedicated to your practice success

ONLY NEUROSTAR PROVIDES...

- More than 100 team members dedicated to growing NeuroStar practices
- Lifetime support with strength in numbers
- On-site service within 24 hours for non-operational NeuroStar Systems

PROGRAMS

Driving market awareness to grow your practice

ONLY NEUROSTAR HAS INCREASED BRAND AWARENESS BY 33% IN 2022 AND HAS...

- 5-STARS Solution
- Precision Pulse Program
- Co-op Marketing
- Stellar Distinctions
Financial Overview
NeuroStar Advanced Therapy for Mental Health
Annual Revenue

Annual Revenue by Geography

Annual Product Revenue (US)
### Worldwide Quarterly Revenue

Q3 2023 Revenue of $17.9M was up 8% from Q3 2022

<table>
<thead>
<tr>
<th>Quarter</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
<th>Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1</td>
<td>$12.3</td>
<td>$14.2</td>
<td>$15.5</td>
<td>$15.5</td>
</tr>
<tr>
<td>Q2</td>
<td>$13.8</td>
<td>$14.2</td>
<td>$16.5</td>
<td>$17.6</td>
</tr>
<tr>
<td>Q3</td>
<td>$15.0</td>
<td>$16.3</td>
<td>$18.2</td>
<td>$17.9</td>
</tr>
<tr>
<td>Q4</td>
<td>$16.5</td>
<td>$18.2</td>
<td>$19.0</td>
<td>$21.0</td>
</tr>
</tbody>
</table>

($ in millions)
## Results of Operations

<table>
<thead>
<tr>
<th></th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenues</strong></td>
<td>$16,498</td>
<td>$17,884</td>
</tr>
<tr>
<td><strong>YOY Growth</strong></td>
<td>8%</td>
<td></td>
</tr>
<tr>
<td><strong>Gross Profit</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Gross Margin</strong></td>
<td>78%</td>
<td>66%</td>
</tr>
<tr>
<td><strong>Operating Expenses:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sales and Marketing</td>
<td>11,643</td>
<td>12,141</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>71%</td>
<td>68%</td>
</tr>
<tr>
<td>General and Administrative</td>
<td>6,391</td>
<td>6,339</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>39%</td>
<td>35%</td>
</tr>
<tr>
<td>Research and Development</td>
<td>2,348</td>
<td>2,155</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>14%</td>
<td>12%</td>
</tr>
<tr>
<td><strong>Total Operating Expenses</strong></td>
<td>20,382</td>
<td>20,635</td>
</tr>
<tr>
<td><strong>Loss from Operations</strong></td>
<td>($7,454)</td>
<td>($8,871)</td>
</tr>
<tr>
<td>% of Revenues</td>
<td>-45%</td>
<td>-50%</td>
</tr>
</tbody>
</table>
## Financial Position

($ in thousands)  

<table>
<thead>
<tr>
<th>Description</th>
<th>As of September 30, 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash and Cash Equivalents</td>
<td>$35,847</td>
</tr>
<tr>
<td>Other Assets</td>
<td>$57,141</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td><strong>$92,988</strong></td>
</tr>
<tr>
<td>Long-term debt, net</td>
<td>$36,851</td>
</tr>
<tr>
<td>Convertible Preferred Stock Warrant Liability</td>
<td>$0</td>
</tr>
<tr>
<td>Convertible Preferred Stock</td>
<td>$0</td>
</tr>
<tr>
<td>Accumulated Deficit</td>
<td>($370,704)</td>
</tr>
<tr>
<td><strong>Total Stockholders’ Equity</strong></td>
<td><strong>$37,941</strong></td>
</tr>
</tbody>
</table>
Local Consumables New MTs (New Patient Starts) & Utilization

Local Consumable Monthly Utilization & New MTs
Jan 2021 - Sept 2023

Utilization  New MT's
## U.S. NeuroStar Treatment Sessions

### Total U.S. Treatment Session Revenues

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1-21</td>
<td>Q2-21</td>
<td>Q3-21</td>
</tr>
<tr>
<td>Total U.S. Treatment Session Revenues ($000)</td>
<td>$9,629</td>
<td>$10,801</td>
<td>$10,259</td>
</tr>
<tr>
<td>YoY ∆</td>
<td>18%</td>
<td>65%</td>
<td>13%</td>
</tr>
</tbody>
</table>

### Average Revenue per Active Site

<table>
<thead>
<tr>
<th></th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Q1-21</td>
<td>Q2-21</td>
<td>Q3-21</td>
</tr>
<tr>
<td>Average Revenue per Active Site ($000) (1)</td>
<td>$10.5</td>
<td>$12.0</td>
<td>$11.2</td>
</tr>
<tr>
<td>YoY ∆</td>
<td>12%</td>
<td>62%</td>
<td>9%</td>
</tr>
</tbody>
</table>

---

(1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter)
## Supplemental Financial and Operating Information

<table>
<thead>
<tr>
<th></th>
<th>2021 Q1</th>
<th>2021 Q2</th>
<th>2021 Q3</th>
<th>2021 Q4</th>
<th>2022 Q1</th>
<th>2022 Q2</th>
<th>2022 Q3</th>
<th>2022 Q4</th>
<th>2023 Q1</th>
<th>2023 Q2</th>
<th>2023 Q3</th>
<th>FY 2021</th>
<th>FY 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Revenue ($ thousands)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total U.S. NeuroStar Advanced Therapy System Revenues</td>
<td>$1,755</td>
<td>$2,577</td>
<td>$2,612</td>
<td>$2,815</td>
<td>$3,642</td>
<td>$4,382</td>
<td>$3,934</td>
<td>$4,616</td>
<td>$3,850</td>
<td>$4,489</td>
<td>$3,597</td>
<td>$9,760</td>
<td>$16,575</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-32%</td>
<td>10%</td>
<td>3%</td>
<td>-22%</td>
<td>108%</td>
<td>70%</td>
<td>51%</td>
<td>64%</td>
<td>6%</td>
<td>2%</td>
<td>-9%</td>
<td>-12%</td>
<td>70%</td>
</tr>
<tr>
<td>Total U.S. Treatment Sessions Revenues</td>
<td>$6,629</td>
<td>$10,801</td>
<td>$10,259</td>
<td>$11,245</td>
<td>$9,469</td>
<td>$11,295</td>
<td>$11,864</td>
<td>$12,450</td>
<td>$10,643</td>
<td>$12,314</td>
<td>$13,060</td>
<td>$41,933</td>
<td>$45,077</td>
</tr>
<tr>
<td>YoY Change</td>
<td>18%</td>
<td>65%</td>
<td>13%</td>
<td>2%</td>
<td>-2%</td>
<td>5%</td>
<td>16%</td>
<td>11%</td>
<td>12%</td>
<td>9%</td>
<td>10%</td>
<td>20%</td>
<td>7%</td>
</tr>
<tr>
<td>Total U.S. Other Revenues</td>
<td>$419</td>
<td>$431</td>
<td>$409</td>
<td>$496</td>
<td>$406</td>
<td>$455</td>
<td>$446</td>
<td>$447</td>
<td>$471</td>
<td>$486</td>
<td>$554</td>
<td>$1,754</td>
<td>$1,754</td>
</tr>
<tr>
<td>YoY Change</td>
<td>7%</td>
<td>13%</td>
<td>1%</td>
<td>25%</td>
<td>-3%</td>
<td>6%</td>
<td>9%</td>
<td>-10%</td>
<td>16%</td>
<td>7%</td>
<td>24%</td>
<td>12%</td>
<td>0%</td>
</tr>
<tr>
<td>Total U.S. Revenues</td>
<td>$11,802</td>
<td>$13,809</td>
<td>$13,280</td>
<td>$14,556</td>
<td>$13,517</td>
<td>$16,132</td>
<td>$16,244</td>
<td>$17,513</td>
<td>$14,964</td>
<td>$17,289</td>
<td>$17,211</td>
<td>$53,447</td>
<td>$63,406</td>
</tr>
<tr>
<td>YoY Change</td>
<td>6%</td>
<td>49%</td>
<td>10%</td>
<td>-3%</td>
<td>15%</td>
<td>17%</td>
<td>22%</td>
<td>20%</td>
<td>11%</td>
<td>7%</td>
<td>6%</td>
<td>12%</td>
<td>19%</td>
</tr>
<tr>
<td>Total International Revenues</td>
<td>$486</td>
<td>$394</td>
<td>$519</td>
<td>$466</td>
<td>$664</td>
<td>$198</td>
<td>$253</td>
<td>$686</td>
<td>$576</td>
<td>$321</td>
<td>$673</td>
<td>$1,865</td>
<td>$1,800</td>
</tr>
<tr>
<td>YoY Change</td>
<td>63%</td>
<td>-17%</td>
<td>24%</td>
<td>-13%</td>
<td>36%</td>
<td>-50%</td>
<td>-51%</td>
<td>47%</td>
<td>-13%</td>
<td>62%</td>
<td>165%</td>
<td>8%</td>
<td>-3%</td>
</tr>
<tr>
<td>Total Revenues</td>
<td>$12,288</td>
<td>$14,203</td>
<td>$13,799</td>
<td>$15,022</td>
<td>$14,181</td>
<td>$16,329</td>
<td>$16,498</td>
<td>$18,199</td>
<td>$15,540</td>
<td>$17,610</td>
<td>$17,884</td>
<td>$55,312</td>
<td>$65,206</td>
</tr>
<tr>
<td>YoY Change</td>
<td>7%</td>
<td>46%</td>
<td>11%</td>
<td>-4%</td>
<td>15%</td>
<td>15%</td>
<td>20%</td>
<td>21%</td>
<td>10%</td>
<td>8%</td>
<td>8%</td>
<td>12%</td>
<td>18%</td>
</tr>
<tr>
<td><strong>U.S. Operating and Financial Metrics</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total NeuroStar Systems</td>
<td>23</td>
<td>36</td>
<td>40</td>
<td>48</td>
<td>46</td>
<td>59</td>
<td>50</td>
<td>58</td>
<td>49</td>
<td>54</td>
<td>43</td>
<td>147</td>
<td>213</td>
</tr>
<tr>
<td>YoY Change</td>
<td>-39%</td>
<td>3%</td>
<td>3%</td>
<td>-11%</td>
<td>100%</td>
<td>64%</td>
<td>25%</td>
<td>21%</td>
<td>7%</td>
<td>-8%</td>
<td>-14%</td>
<td>-11%</td>
<td>45%</td>
</tr>
<tr>
<td>Average Revenue Per Active Site ($) (1)</td>
<td>$10,512</td>
<td>$12,001</td>
<td>$11,163</td>
<td>$12,183</td>
<td>$9,874</td>
<td>$11,280</td>
<td>$11,364</td>
<td>$11,517</td>
<td>$9,667</td>
<td>$11,391</td>
<td>$11,916</td>
<td>$36,127</td>
<td>$36,916</td>
</tr>
<tr>
<td>YoY Change</td>
<td>12%</td>
<td>62%</td>
<td>9%</td>
<td>0.4%</td>
<td>-6%</td>
<td>-6%</td>
<td>2%</td>
<td>-5%</td>
<td>-2%</td>
<td>1%</td>
<td>5%</td>
<td>-11%</td>
<td>45%</td>
</tr>
</tbody>
</table>

(1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period)